NEUROONE MEDICAL TECHNOLOGIE
NMTCNASDAQTrading Snapshot
- Day Range
- $1.07 – $1.09
- 52-Week Range
- $1.28 – $6.96
- Volume
- $7.15B
- Avg Volume
- $6.15B
- Shares Outstanding
- 8.7M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $10M
- Last Q Revenue
- $3M
- P/E Ratio
- —
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-0.84
- Dividend Yield
- —
- Dilution (1yr)
- +63.0%
Why Investors Own NMTC
- ✓High-growth profile — revenue up +40.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 49% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEUROONE MEDICAL TECHNOLOGIE
NMTC
StockOtter · stockotter.spaceAbout NEUROONE MEDICAL TECHNOLOGIE
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
NEUROONE MEDICAL TECHNOLOGIE tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift NMTC price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
NEUROONE MEDICAL TECHNOLOGIE announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.